3D Models as a Tool to Assess the Anti-Tumor Efficacy of Therapeutic Antibodies: Advantages and Limitations.
3D models
drug response
therapeutic monoclonal antibodies
tumor microenvironment
Journal
Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489
Informations de publication
Date de publication:
08 Jul 2022
08 Jul 2022
Historique:
received:
01
06
2022
revised:
30
06
2022
accepted:
06
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Therapeutic monoclonal antibodies (mAbs) are an emerging and very active frontier in clinical oncology, with hundred molecules currently in use or being tested. These treatments have already revolutionized clinical outcomes in both solid and hematological malignancies. However, identifying patients who are most likely to benefit from mAbs treatment is currently challenging and limiting the impact of such therapies. To overcome this issue, and to fulfill the expectations of mAbs therapies, it is urgently required to develop proper culture models capable of faithfully reproducing the interactions between tumor and its surrounding native microenvironment (TME). Three-dimensional (3D) models which allow the assessment of the impact of drugs on tumors within its TME in a patient-specific context are promising avenues to progressively fill the gap between conventional 2D cultures and animal models, substantially contributing to the achievement of personalized medicine. This review aims to give a brief overview of the currently available 3D models, together with their specific exploitation for therapeutic mAbs testing, underlying advantages and current limitations to a broader use in preclinical oncology.
Identifiants
pubmed: 35892706
pii: antib11030046
doi: 10.3390/antib11030046
pmc: PMC9326665
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Nat Rev Cancer. 2021 Oct;21(10):669-680
pubmed: 34272515
Bioengineering (Basel). 2020 Sep 17;7(3):
pubmed: 32957528
Br Med Bull. 2012;104:41-59
pubmed: 23118261
Sci Rep. 2018 Oct 9;8(1):15010
pubmed: 30301942
PLoS One. 2017 Jan 13;12(1):e0169797
pubmed: 28085924
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Nat Rev Neurol. 2021 Jul;17(7):399-414
pubmed: 34075251
Blood. 2013 May 23;121(21):e129-37
pubmed: 23471306
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Adv Drug Deliv Rev. 2014 Dec 15;79-80:40-9
pubmed: 24996134
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
Cancer Res. 2005 Apr 15;65(8):3257-63
pubmed: 15833858
Front Immunol. 2021 May 03;12:639572
pubmed: 34012434
J Cell Sci. 2022 Jan 15;135(2):
pubmed: 34982151
Nat Rev Immunol. 2018 Mar;18(3):195-203
pubmed: 29332937
Mol Immunol. 2015 Oct;67(2 Pt A):28-45
pubmed: 25911943
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23
pubmed: 24217204
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Biomaterials. 2020 Jul;247:119960
pubmed: 32278822
Haematologica. 2018 Apr;103(4):707-716
pubmed: 29326121
Methods Mol Biol. 2017;1612:177-190
pubmed: 28634943
Cancers (Basel). 2021 Feb 19;13(4):
pubmed: 33669619
Nat Rev Immunol. 2021 Jun;21(6):382-393
pubmed: 33875867
Curr Opin Rheumatol. 2020 Nov;32(6):597-608
pubmed: 32890026
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Cell. 2017 Sep 7;170(6):1120-1133.e17
pubmed: 28803728
Front Bioeng Biotechnol. 2019 Sep 12;7:217
pubmed: 31572718
Cancer Discov. 2021 Apr;11(4):933-959
pubmed: 33811125
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
J Cell Sci. 2017 Jan 1;130(1):203-218
pubmed: 27663511
Curr Opin Oncol. 2021 Sep 1;33(5):513-519
pubmed: 34310410
Nat Rev Drug Discov. 2022 Nov;21(11):793-794
pubmed: 34759309
Cancers (Basel). 2021 Jul 08;13(14):
pubmed: 34298648
J Immunol. 2016 Apr 1;196(7):3199-211
pubmed: 26921308
Science. 2005 Jan 7;307(5706):58-62
pubmed: 15637262
Front Immunol. 2021 Nov 18;12:798493
pubmed: 34868086
Nat Med. 2011 Nov 07;17(11):1359-70
pubmed: 22064426
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Tissue Eng Part B Rev. 2014 Dec;20(6):555-66
pubmed: 24597549
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34815357
NPJ Precis Oncol. 2020 Jul 27;4:18
pubmed: 32793806
Eur J Cancer. 2020 Mar;128:107-118
pubmed: 32037061
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214
pubmed: 33437048
Cancer Res. 2018 May 1;78(9):2159-2165
pubmed: 29653942
Trends Immunol. 2021 Apr;42(4):293-311
pubmed: 33714688
Front Immunol. 2021 Feb 08;11:605231
pubmed: 33628205
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Biosensors (Basel). 2021 Nov 11;11(11):
pubmed: 34821661
Ann Rheum Dis. 2019 Jun;78(6):862-864
pubmed: 30487147
Semin Immunol. 2018 Dec;40:74-82
pubmed: 30409538
J Immunother Cancer. 2019 Mar 14;7(1):74
pubmed: 30871626
Blood. 2018 Jan 4;131(1):13-29
pubmed: 29118010
Nat Rev Clin Oncol. 2022 Jan;19(1):37-50
pubmed: 34580473
PLoS One. 2013 Aug 26;8(8):e71613
pubmed: 23990965
Nat Rev Clin Oncol. 2009 Jul;6(7):395-404
pubmed: 19424102
Nat Rev Rheumatol. 2018 Oct;14(10):580-591
pubmed: 30108367
Nat Rev Cancer. 2016 Dec;16(12):759-773
pubmed: 27687979
Haematologica. 2021 Sep 01;106(9):2334-2344
pubmed: 32732361
Sci Rep. 2019 May 9;9(1):7154
pubmed: 31073193
Front Immunol. 2020 Dec 23;11:564887
pubmed: 33424829
Tissue Eng Part A. 2009 Mar;15(3):559-67
pubmed: 18724832
Biotechnol Annu Rev. 2008;14:275-96
pubmed: 18606368
Methods Mol Biol. 2016;1464:13-24
pubmed: 27858352
Nat Rev Rheumatol. 2021 Apr;17(4):213-223
pubmed: 33686279
Eur J Pharmacol. 2015 Jul 15;759:19-29
pubmed: 25823812
J Leukoc Biol. 2020 Aug;108(2):591-599
pubmed: 32056262
Nat Rev Drug Discov. 2021 Jul;20(7):491-495
pubmed: 33953368
Nat Rev Mol Cell Biol. 2007 Oct;8(10):839-45
pubmed: 17684528
Methods Mol Biol. 2011;695:17-39
pubmed: 21042963
Int Immunol. 2021 Mar 1;33(3):127-148
pubmed: 33337480
Expert Opin Biol Ther. 2016 Oct;16(10):1239-44
pubmed: 27382931
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
MAbs. 2022 Jan-Dec;14(1):2014296
pubmed: 35030985
Cells. 2021 Mar 04;10(3):
pubmed: 33806310
Front Cardiovasc Med. 2022 Mar 04;9:847554
pubmed: 35310996
Arch Biochem Biophys. 2012 Oct 15;526(2):146-53
pubmed: 22387378
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Nat Methods. 2007 Apr;4(4):359-65
pubmed: 17396127
Cancers (Basel). 2021 Jan 26;13(3):
pubmed: 33530653
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30
pubmed: 26578779
Trends Cardiovasc Med. 1993 Nov-Dec;3(6):244-50
pubmed: 21244915
Br J Haematol. 2018 Jul;182(1):29-45
pubmed: 29741753
Nat Rev Cancer. 2020 Jul;20(7):383-397
pubmed: 32341551
Nat Rev Cancer. 2021 Aug;21(8):481-499
pubmed: 34083781
Am J Hematol. 2020 May;95(5):548-567
pubmed: 32212178
Haematologica. 2022 Apr 01;107(4):909-920
pubmed: 34109776
Front Immunol. 2018 May 08;9:998
pubmed: 29867975
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Cell. 2018 Nov 29;175(6):1452-1454
pubmed: 30500529
Transl Oncol. 2021 Apr;14(4):101015
pubmed: 33493799
ACS Biomater Sci Eng. 2016 Oct 10;2(10):1710-1721
pubmed: 28251176
Anticancer Res. 2017 Nov;37(11):5935-5939
pubmed: 29061772
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
Front Med. 2021 Dec;15(6):805-828
pubmed: 34874513
Biotechnol Bioeng. 2019 Jan;116(1):206-226
pubmed: 30367820
Cell. 2019 Jun 13;177(7):1701-1713.e16
pubmed: 31155232
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
Nat Commun. 2020 Oct 16;11(1):5224
pubmed: 33067467
Drug Resist Updat. 2003 Jun;6(3):129-36
pubmed: 12860460
Adv Immunol. 2006;90:297-339
pubmed: 16730267
Lancet Oncol. 2017 Feb;18(2):e113-e125
pubmed: 28214412
J Immunol. 2016 Aug 1;197(3):807-13
pubmed: 27316683
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Biostatistics. 2019 Apr 1;20(2):273-286
pubmed: 29394327
Front Immunol. 2020 Dec 10;11:603640
pubmed: 33362787
Rheumatology (Oxford). 2022 Apr 11;61(4):e93-e96
pubmed: 34919661
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Nat Rev Drug Discov. 2016 Jun;15(6):379-80
pubmed: 27199245
Haematologica. 2020 Apr;105(4):1032-1041
pubmed: 31296574
Signal Transduct Target Ther. 2022 Feb 7;7(1):39
pubmed: 35132063
Cancer Cell. 2021 Aug 9;39(8):1023-1027
pubmed: 33989512